The use of major analgesics in patients with renal dysfunction

Current Drug Targets

Volumn 11, Issue 6, 2010, Pages 752-758

  Niscola, Pasquale ^a   Scaramucci, Laura ^a   Vischini, Gisella ^a   Giovannini, Marco ^a   Ferrannini, Michele ^a   Massa, Pasquale ^a   Tatangelo, Paola ^a   Galletti, Massimo ^a   Palumbo, Roberto ^a  

^a S EUGENIO HOSPITAL   (Italy)

Author keywords

Analgesia; Analgesics; Buprenorphine; Dialysis kidney; Morphine; Opioids; Oxycodone; Pain; Renal failure

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; CODEINE; CODEINE 6 GLUCURONIDE; DEXTROPROPOXYPHENE; DRUG METABOLITE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; NORPETHIDINE; NORPROPOXYPHENE; OPIATE; OXYCODONE; PETHIDINE; SUFENTANIL; TRAMADOL;

ANALGESIA; ARTICLE; CANCER PAIN; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DEPRESSION; CHRONIC PAIN; CONFUSION; CREATININE BLOOD LEVEL; DELIRIUM; DISTRIBUTION VOLUME; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG USE; EPILEPTIC STATE; EVIDENCE BASED PRACTICE; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION TEST; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUROTOXICITY; PAIN; PATIENT MONITORING; RESPIRATION DEPRESSION; RISK ASSESSMENT; SEDATION; SEIZURE; SIDE EFFECT; SWEATING; TREATMENT CONTRAINDICATION; TREMOR; VOMITING; XEROSTOMIA;

ANALGESICS; HUMANS; KIDNEY DISEASES; PAIN;

EID: 77949449581     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791170879     Document Type: Article

References (74)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. J Am Med Assoc 2007; 298: 2038-47.
2. Baile GR, Mason NA, Bragg-Gresham JL, Gillespie BW, Young EW. Analgesic prescription patterns among hemodialysis patients in the DOPPS: Potential for underprescription. Kidney Int 2004; 65: 2419-25.
3. Droney J, Levy J, Quigley C. Prescribing opioids in renal failure. J Opioid Manag 2007; 3: 309-16.
4. Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008; 8: 287-313.
5. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of the American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Phys 2008; 11(2 Suppl): S5-S62.
6. Vadivelu N, Hines RL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging 2008; 3: 421-30.
7. Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004; 5: 2-19.
8. Mercadante S, Ferrantelli A, Tortorici C, et al. Incidence of chronic pain in patients with end-stage renal disease on dialysis. J Pain Symptom Manage 2005; 30: 302-4.
9. Innis J. Pain assessment and management for a dialysis patient with diabetic peripheral neuropathy. CANNT J 2006; 16(2):12-7, 20-6.; quiz 18-9, 27-8.
10. Weisbord SD, Fried LF, Arnold RM, et al. Prevalence, severity, importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol 2005; 16: 2487-94.
11. Cohen LM, Moss AH, Weisbord SD, Germain MJ. Renal palliative care. J Palliat Med 2006; 9(4): 977-92.
12. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28: 497-504.
13. Böger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med 2006; 20 Suppl 1: s17-23.
14. Hardy JR, Herbert AR, Reymond E. Opioids in patients on renal dialysis. J Pain Symptom Manage 2007; 33(1): 1-2.
15. Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31(6): 410-22.
16. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Phys 2008; 11(2 Suppl): S133-53.
17. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84(5): 587-93.
18. Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intens Care 2005; 33(3): 311-22.
19. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother 2007; 21(2): 5-16.
20. Mercadante S, Caligara M, Sapio M, Serretta R, Lodi F. Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. J Pain Symptom Manage 1997; 13(4): 241-4.
21. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Phys 2008; 11(2 Suppl): S133-53.
22. Murtagh FE, Addington-Hall JM, Donohoe P, Higginson IJ. Symptom management in patients with established renal failure managed without dialysis. EDTNA ERCA J 2006; 32(2): 93-8.
23. Gonçalves F. Morphine toxicity in renal failure. J Opioid Manag 2006; 2(3): 174-6.
24. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19(9): 2542-54.
25. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001; 323: 334-6.
26. Stevens LA, Levey AS. Measurement of kidney function. Med Clin North Am 2005; 89(3): 457-73.
27. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31-41.
28. Stevens LA, Zhang Y, Schmid CH. Evaluating the performance of equations for estimating glomerular filtration rate. J Nephrol 2008; 21(6): 797-807.
29. Murtagh F, Edmonds P, Farnham C. Opioids in special circumstances. In Forbes K: Opioids in Cancer Pain, Oxford University Press, Oxford, 2007, pp 131-143.
30. Chan GL, Matzke GR. Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm 1987; 21(10): 773-83.
31. Lötsch J. Opioid metabolites. J Pain Symptom Manage 2005; 29(5 Suppl): S10-24.
32. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Phys 2008;11(2 Suppl): S133-53.
33. Barakzoy AS, Moss AH. Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease. J Am Soc Nephrol 2006; 17(11): 3198-203.
34. Verwey-van Wissen CP, Koopman-Kimenai PM, Vree TB. Direct determination of codeine, norcodeine, morphine and normorphine with their corresponding O-glucuronide conjugates by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1991; 570(2): 309-20.
35. Vree TB, van Dongen RT, Koopman-Kimenai PM. Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract 2000; 54(6): 395-8.
36. Guay DR, Awni WM, Findlay JW, et al. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 1988; 43(1):63-71.
37. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Phys 2008; 11(2 Suppl): S105-20.
38. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenom J 2007; 7(4): 257-65.
39. Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993; 46(2): 313-40.
40. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43(13): 879-923.
41. Gardner JS, Blough D, Drinkard CR, et al. Tramadol and seizures: a surveillance study in a managed care population. Pharmacotherapy 2000; 20(12): 1423-31.
42. Barnung SK, Treschow M, Borgbjerg FM. Respiratory depression following oral tramadol in a patient with impaired renal function. Pain 1997; 71(1): 111-2.
43. Izzedine H, Launay-Vacher V, Abbara C, Aymard G, Bassilios N, Deray G. Pharmacokinetics of tramadol in a hemodialysis patient. Nephron 2002; 92(3): 755-6.
44. Bailie GR, Johnson CA. Safety of propoxyphene in dialysis patients. Semin Dial 2002; 15(5): 375.
45. Hanlon JT, Aspinall SL, Semla TP, et al. Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc 2009; 57(2): 335-40.
46. Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13(2):180-5.
47. O'Connor AB, Lang VJ, Quill TE. Eliminating analgesic meperidine use with a supported formulary restriction. Am J Med 2005; 118: 885-9.
48. Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 2002; 95(1): 203-8.
49. van Dorp EL, Morariu A, Dahan A. Morphine-6-glucuronide: potency and safety compared with morphine. Expert Opin Pharmacother 2008; 9(11): 1955-61.
50. Osborne R, Joel S, Grebenik K, Trew D, Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 1993; 54(2): 158-67.
51. Kurella M, Bennett W, Chertow G. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis 2003; 42(2): 217-28.
52. Riley J, Eisenberg E, Müller-Schwefe G, Drewes AM, Arendt-Nielsen L. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin 2008; 24(1): 175-92.
53. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006; 79(5): 461-79.
54. Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmaco-kinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996; (1): 3-8.
55. Lee MA, Leng ME, Cooper RM. Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis. Palliat Med 2005; 19(3): 259-60.
56. Foral PA, Ineck JR, Nystrom KK. Oxycodone accumulation in a hemodialysis patient. South Med J 2007; 100(2): 212-4.
57. Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage 2005; 29(5 Suppl): S57-66.
58. Sloan PA, Barkin RL. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. J Opioid Manag 2008; 4(3): 131-44.
59. Vadalouca A, Moka E, Argyra E, Sikioti P, Siafaka I. Opioid rotation in patients with cancer: a review of the current literature. J Opioid Manag 2008; 4(4): 213-50.
60. Razaq M, Balicas M, Mankan N. Use of hydromorphone (Dilaudid) and morphine for patients with hepatic and renal impairment. Am J Ther 2007; 14(4): 414-6.
61. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000; 27(7): 524-8.
62. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005; 19(4): 13-24.
63. Furlan V, Hafi A, Dessalles MC, Bouchez J, Charpentier B, Taburet AM. Methadone is poorly removed by haemodialysis. Nephrol Dial Transplant 1999; 14(1): 254-5.
64. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 2000; 38(1): 59-89.
65. Messina J, Darwish M, Fine PG. Fentanyl buccal tablet. Drugs Today (Barc) 2008; 44(1): 41-54.
66. Fyman PN, Reynolds JR, Moser F, Avitable M, Casthely PA, Butt K. Pharmacokinetics of sufentanil in patients undergoing renal transplantation. Can J Anaesth 1988; 35 (31): 312-5.
67. Bastani B, Jamal JA. Removal of morphine but not fentanyl during haemodialysis. Nephrol Dial Transplant 1997; 12(12): 2802-4.
68. Joh J, Sila MK, Bastani B. Nondialyzability of fentanyl with high-efficiency and high-flux membranes. Anesth Analg 1998; 86(2): 447.
69. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009; 13(3): 219-30.
70. Vadivelu N, Hines RL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging 2008; 3(3): 421-30.
71. Aurilio C, Pace MC, Pota V, et al. Opioids switching with transdermal systems in chronic cancer pain. J Exp Clin Cancer Res 2009; 28: 61.
72. Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990; 64(3): 276-82.
73. Filitz J, Griessinger N, Sittl R, Likar R, Schüttler J, Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain 2006; 10(8): 743-8.
74. Pergolizzi JV, Mercadante S, Echaburu AV, et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Curr Med Res Opin 2009; 25(6): 1517-28.